Go Pro
→ Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid (From Altimetry) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bioxytran, Inc. stock logo
BIXT
Bioxytran
$0.02
+4.0%		$0.02
$0.02
▼
$0.09
$2.41M1.88140,080 shs69,990 shs
Imunon, Inc. stock logo
IMNN
Imunon
$1.58
+1.3%		$1.70
$1.47
▼
$6.03
$8.75M1.9852,127 shs34,009 shs
MetaVia Inc. stock logo
MTVA
MetaVia
$1.75
-4.9%		$1.58
$0.97
▼
$19.03
$9.50M0.9480,965 shs80,688 shs
Xenetic Biosciences, Inc. stock logo
XBIO
Xenetic Biosciences
$4.67
+0.9%		$3.15
$1.90
▼
$13.93
$10.61M2.2372,062 shs79,153 shs
The Best Nuclear Energy Stocks to Buy Cover
The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bioxytran, Inc. stock logo
BIXT
Bioxytran
+3.96%-7.08%-4.55%-31.82%-72.00%
Imunon, Inc. stock logo
IMNN
Imunon
+1.28%-1.25%-0.63%-23.30%-72.43%
MetaVia Inc. stock logo
MTVA
MetaVia
-4.89%+2.94%+17.45%-31.91%-76.24%
Xenetic Biosciences, Inc. stock logo
XBIO
Xenetic Biosciences
+0.86%+17.34%+57.77%+51.13%+53.87%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bioxytran, Inc. stock logo
BIXT
Bioxytran
$0.02
+4.0%		$0.02
$0.02
▼
$0.09
$2.41M1.88140,080 shs69,990 shs
Imunon, Inc. stock logo
IMNN
Imunon
$1.58
+1.3%		$1.70
$1.47
▼
$6.03
$8.75M1.9852,127 shs34,009 shs
MetaVia Inc. stock logo
MTVA
MetaVia
$1.75
-4.9%		$1.58
$0.97
▼
$19.03
$9.50M0.9480,965 shs80,688 shs
Xenetic Biosciences, Inc. stock logo
XBIO
Xenetic Biosciences
$4.67
+0.9%		$3.15
$1.90
▼
$13.93
$10.61M2.2372,062 shs79,153 shs
The Best Nuclear Energy Stocks to Buy Cover
The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bioxytran, Inc. stock logo
BIXT
Bioxytran
+3.96%-7.08%-4.55%-31.82%-72.00%
Imunon, Inc. stock logo
IMNN
Imunon
+1.28%-1.25%-0.63%-23.30%-72.43%
MetaVia Inc. stock logo
MTVA
MetaVia
-4.89%+2.94%+17.45%-31.91%-76.24%
Xenetic Biosciences, Inc. stock logo
XBIO
Xenetic Biosciences
+0.86%+17.34%+57.77%+51.13%+53.87%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Bioxytran, Inc. stock logo
BIXT
Bioxytran
0.00
N/AN/AN/A
Imunon, Inc. stock logo
IMNN
Imunon
2.00
Hold$10.00532.91% Upside
MetaVia Inc. stock logo
MTVA
MetaVia
2.00
Hold$20.001,042.86% Upside
Xenetic Biosciences, Inc. stock logo
XBIO
Xenetic Biosciences
1.00
SellN/AN/A

Current Analyst Ratings Breakdown

Latest BIXT, XBIO, IMNN, and MTVA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/21/2026
MetaVia Inc. stock logo
MTVA
MetaVia
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
7/17/2026
Imunon, Inc. stock logo
IMNN
Imunon
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
7/17/2026
Xenetic Biosciences, Inc. stock logo
XBIO
Xenetic Biosciences
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
7/10/2026
MetaVia Inc. stock logo
MTVA
MetaVia
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
(Data available from 9/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Bioxytran, Inc. stock logo
BIXT
Bioxytran
N/AN/AN/AN/A($0.04) per shareN/A
Imunon, Inc. stock logo
IMNN
Imunon
N/AN/AN/AN/A$0.35 per shareN/A
MetaVia Inc. stock logo
MTVA
MetaVia
N/AN/AN/AN/A$1.32 per shareN/A
Xenetic Biosciences, Inc. stock logo
XBIO
Xenetic Biosciences
$3.26M3.28N/AN/A$2.65 per share1.76
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Bioxytran, Inc. stock logo
BIXT
Bioxytran
-$2.12M-$0.03N/AN/AN/AN/AN/A-792.61%N/A
Imunon, Inc. stock logo
IMNN
Imunon
-$14.49M-$3.83N/AN/AN/AN/A-358.01%-132.91%11/12/2026 (Estimated)
MetaVia Inc. stock logo
MTVA
MetaVia
-$12.97M-$3.23N/AN/AN/AN/A-209.67%-107.91%11/5/2026 (Estimated)
Xenetic Biosciences, Inc. stock logo
XBIO
Xenetic Biosciences
-$2.68M-$1.16N/AN/AN/A-75.90%-40.62%-34.97%11/6/2026 (Estimated)

Latest BIXT, XBIO, IMNN, and MTVA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2026Q2 2026
Bioxytran, Inc. stock logo
BIXT
Bioxytran
N/A-$0.01N/A-$0.01N/AN/A
8/11/2026Q2 2026
Imunon, Inc. stock logo
IMNN
Imunon
-$0.8675-$0.54+$0.3275-$0.54N/AN/A
8/6/2026Q2 2026
MetaVia Inc. stock logo
MTVA
MetaVia
-$0.82-$0.90-$0.08-$0.90N/AN/A
8/6/2026Q2 2026
Xenetic Biosciences, Inc. stock logo
XBIO
Xenetic Biosciences
N/A-$0.41N/A-$0.41N/A$0.66 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Bioxytran, Inc. stock logo
BIXT
Bioxytran
N/AN/AN/AN/AN/A
Imunon, Inc. stock logo
IMNN
Imunon
N/AN/AN/AN/AN/A
MetaVia Inc. stock logo
MTVA
MetaVia
N/AN/AN/AN/AN/A
Xenetic Biosciences, Inc. stock logo
XBIO
Xenetic Biosciences
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Bioxytran, Inc. stock logo
BIXT
Bioxytran
N/A
0.03
0.03
Imunon, Inc. stock logo
IMNN
Imunon
2.86
1.82
1.82
MetaVia Inc. stock logo
MTVA
MetaVia
N/A
2.06
2.06
Xenetic Biosciences, Inc. stock logo
XBIO
Xenetic Biosciences
N/A
7.43
7.43

Institutional Ownership

CompanyInstitutional Ownership
Bioxytran, Inc. stock logo
BIXT
Bioxytran
N/A
Imunon, Inc. stock logo
IMNN
Imunon
4.47%
MetaVia Inc. stock logo
MTVA
MetaVia
1.37%
Xenetic Biosciences, Inc. stock logo
XBIO
Xenetic Biosciences
15.12%

Insider Ownership

CompanyInsider Ownership
Bioxytran, Inc. stock logo
BIXT
Bioxytran
70.00%
Imunon, Inc. stock logo
IMNN
Imunon
2.83%
MetaVia Inc. stock logo
MTVA
MetaVia
0.60%
Xenetic Biosciences, Inc. stock logo
XBIO
Xenetic Biosciences
7.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
Bioxytran, Inc. stock logo
BIXT
Bioxytran
2114.70 million34.41 millionNot Optionable
Imunon, Inc. stock logo
IMNN
Imunon
305.61 million5.45 millionNot Optionable
MetaVia Inc. stock logo
MTVA
MetaVia
85.16 million5.13 millionN/A
Xenetic Biosciences, Inc. stock logo
XBIO
Xenetic Biosciences
42.29 million2.12 millionNot Optionable

Recent News About These Companies

Xenetic Biosciences Inc.
 |  barrons.comhttps://www.barrons.com/market-data/stocks/xbio/company-people
Xenetic Biosciences, Inc. (NASDAQ:XBIO) Sees Large Increase in Short Interest
August 27, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30986685
Xenetic Biosciences Reports Second Quarter 2026 Financial Results and Highlights Strengthened Scientific Foundation Supporting Continued Advancement of Proprietary DNase Platform
August 7, 2026  |  accessnewswire.comA
Xenetic Biosciences, Inc. Announces That Its Collaboration Partner Received Approval From the Israeli Ministry of Health to Conduct Exploratory, Investigator Initiated Study of ...
June 4, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/sectors/healthcare/articles/xenetic-biosciences-inc-announces-collaboration-124000825.html
Xenetic Biosciences, Inc. Announces That Its Collaboration Partner Received Approval From the Israeli Ministry of Health to Conduct Exploratory, Investigator Initiated Study of DNase I In Combination With Anti-CD19 CAR T Cells in Large B-Cell Lymphoma
June 4, 2026  |  accessnewswire.comA
Xenetic Biosciences Showcases Compelling ASCO 2026 Data Demonstrating DNase I Significantly Enhances CAR-T Cell Persistence, Tumor Control, and Survival
June 1, 2026  |  accessnewswire.comA
Xenetic Biosciences Reports First Quarter 2026 Financial Results and Highlights Continued Advancement of DNase Oncology Platform
May 13, 2026  |  accessnewswire.comA
Xenetic Biosciences: Q1 Earnings Snapshot
May 12, 2026  |  wtop.comW
Xenetic Biosciences Grants Equity Award to Interim CEO
April 27, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/XBIO/pressreleases/1520659/xenetic-biosciences-grants-equity-award-to-interim-ceo/
Xenetic Biosciences, Inc. Announces Abstract Acceptance for Presentation at the 2026 ASCO Annual Meeting
April 22, 2026  |  accessnewswire.comA
Xenetic Biosciences, Inc. Reports Full Year 2025 Financial Results
March 13, 2026  |  accessnewswire.comA
Xenetic Biosciences, Inc. Announces Adjournment of 2025 Annual Meeting
December 11, 2025  |  accessnewswire.comA
Xenetic extends R&D collaboration with The Scripps Research Institute
November 19, 2025  |  msn.comhttps://www.msn.com/en-us/technology/biotechnology/xenetic-extends-r-d-collaboration-with-the-scripps-research-institute/ar-AA1QKDxC
Xenetic Biosciences, Inc. Extends Research and Development Collaboration with Institute Investigator at Scripps Research to Advance DNase Platform
November 19, 2025  |  accessnewswire.comA
Xenetic Biosciences, Inc. Reports Third Quarter 2025 Financial Results
November 13, 2025  |  accessnewswire.comA
Xenetic Biosciences Announces Public Offering Pricing
October 14, 2025  |  msn.comhttps://www.msn.com/en-us/money/savingandinvesting/xenetic-biosciences-announces-public-offering-pricing/ar-AA1Ossgk
Xenetic 735,000 share Spot Secondary priced at $6.12
October 10, 2025  |  msn.comhttps://www.msn.com/en-us/money/topstocks/xenetic-735000-share-spot-secondary-priced-at-612/ar-AA1Oeziy
Micron, Galecto And Xenetic Lead This Week's Benzinga Stock Ranking Surges
October 10, 2025  |  benzinga.comhttps://www.benzinga.com/trading-ideas/movers/25/10/48161813/micron-galecto-and-xenetic-lead-this-weeks-benzinga-stock-ranking-surges
Xenetic Biosciences, Inc. Announces Pricing of $4.5 Million Underwritten Offering of Common Stock
October 10, 2025  |  accessnewswire.comA
Xenetic Biosciences, Inc. Reports Second Quarter 2025 Financial Results
August 13, 2025  |  accessnewswire.comA

New MarketBeat Followers Over Time

Media Sentiment Over Time

Bioxytran stock logo

Bioxytran OTCMKTS:BIXT

$0.02 +0.00 (+3.96%)
As of 09/4/2026 12:20 PM Eastern

Bioxytran, Inc., a clinical stage pharmaceutical company, focuses on the development, manufacture, and commercialization of therapeutic drugs to address hypoxia in humans. The company's lead drug candidate is BXT-25, an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer for use in the treatment of hypoxic conditions in the brain resulting from stroke, and hypoxic conditions in wounds to prevent necrosis and to promote healing. It is also developing ProLectin-Rx, a polysaccharide derived from pectin that binds to, and blocks the activity of galectin-1, a type of galectin for treatment of mild to moderate cases of Covid-19. The company was founded in 2008 and is headquartered in Needham, Massachusetts.

Imunon stock logo

Imunon NASDAQ:IMNN

$1.58 +0.02 (+1.28%)
As of 09/4/2026 04:00 PM Eastern

Imunon, Inc., a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company's lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma. In addition, the company develops non-viral DNA technology across four modalities, such as TheraPlas for the coding of proteins and cytokines in the treatment of solid tumors; PlaCCine for the coding of viral antigens that can elicit a strong immunological response; FixPlas for the application of Imunon's DNA technology to produce universal cancer vaccines; and IndiPlas, which is in the discovery phase for the development of personalized cancer vaccines or neoepitope cancer vaccines. Imunon, Inc. was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. The company was founded in 1982 and is headquartered in Lawrenceville, New Jersey.

MetaVia stock logo

MetaVia NASDAQ:MTVA

$1.75 -0.09 (-4.89%)
As of 09/4/2026 04:00 PM Eastern

MetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc., formerly known as NeuroBo Pharmaceuticals Inc., is based in CAMBRIDGE, Mass.

Xenetic Biosciences stock logo

Xenetic Biosciences NASDAQ:XBIO

$4.67 +0.04 (+0.86%)
As of 09/4/2026 04:00 PM Eastern

Xenetic Biosciences, Inc. is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas